financetom
Business
financetom
/
Business
/
Why Symbotic Stock Is Trading Lower Tuesday
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Why Symbotic Stock Is Trading Lower Tuesday
Jul 30, 2024 10:38 AM

Symbotic, Inc. ( SYM ) stock is trading lower Tuesday after the company reported worse-than-expected 2024 fiscal year third quarter earnings and issued fourth quarter guidance below estimates.

What Happened: On Monday after the market closed, Symbotic ( SYM ) reported third quarter financial earnings, including a loss of two cents per share missing analyst estimates of a loss of one cent per share.

In addition, the company reported sales of $491.86 million beating analyst estimates of $464.55 million. Also, the company reported a net loss of $14 million and adjusted EBITDA of $15 million for the quarter.

For the fourth quarter, the company sees revenue between $455 million and $465 million versus analyst estimates of $516.84 million.

“Symbotic continues to innovate. During the quarter, we extended the future capabilities of SymBot by incorporating an enhanced sensor array and we advanced development of our new minibot for BreakPack,” said Rick Cohen, Chairman and CEO of Symbotic ( SYM ).

“Our teams continue to focus on execution of the 39 systems we have in deployment, which is reflected in our record revenue for the quarter. Our system gross margin fell below expectations due to elongated construction schedules and implementation costs. We are focused on improving our planning, speed of implementation and project management to improve performance.”

Analyst Changes: Following the earnings report, multiple analysts issued price target changes:

Needham analyst James Ricchiuti maintains Symbotic ( SYM ) with a Buy and lowers the price target from $54 to $40.

Cantor Fitzgerald analyst Derek Soderberg reiterates Symbotic ( SYM ) with a Overweight and maintains $60 price target.

Craig-Hallum analyst Greg Palm maintains Symbotic ( SYM ) with a Buy and lowers the price target from $54 to $45.

See Also: Nasdaq, S&P Futures Rise As Microsoft, AMD Earnings Take Spotlight: Will Fed Provide ‘Turbo Boost’ For Market? Analyst Weighs In

SYM Price Action: At the time of writing, Symbotic ( SYM ) stock is trading 23.4% lower at $27.28, according to data from Benzinga Pro.

Image: 777546 from Pixabay

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Jubilant Bhartia Group buys 40% stake in Coca-Cola's Indian bottler
Jubilant Bhartia Group buys 40% stake in Coca-Cola's Indian bottler
Dec 11, 2024
Dec 11 (Reuters) - Jubilant Bhartia Group said on Wednesday it will buy a 40% stake in Hindustan Coca-Cola Beverages, the largest Coca-Cola bottler in India. ...
Intel Downgraded to BBB Rating Over High Industry Costs Amid Management Uncertainty, S&P Says
Intel Downgraded to BBB Rating Over High Industry Costs Amid Management Uncertainty, S&P Says
Dec 11, 2024
06:19 AM EST, 12/11/2024 (MT Newswires) -- Intel ( INTC ) was downgraded to S&P's BBB rating from BBB+ over a slow industry recovery and higher-than-expected manufacturing costs that are expected to last through 2025, the rating agency said Tuesday. Intel's ( INTC ) discretionary cash flow, or DCF, is expected to improve amid the chipmaker's cost-cutting efforts, but its...
Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend
Myriad Genetics Expects to Reach Resolution With UnitedHealthcare Over Pharmacogenetic Testing Before Yearend
Dec 11, 2024
06:13 AM EST, 12/11/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said late Tuesday that it seeks to reach a resolution with UnitedHealth Group's ( UNH ) UnitedHealthcare on medical policy for pharmacogenetic tests, including Myriad's GeneSight test, before the yearend, but discussions may continue into early next year. We remain steadfast in our confidence in the clinical validity...
Exclusive-Trump tariff plan puts $3 billion in Diageo, Becle tequila imports at risk
Exclusive-Trump tariff plan puts $3 billion in Diageo, Becle tequila imports at risk
Dec 11, 2024
LONDON (Reuters) - Some $3 billion in tequila and mezcal imports from top makers of the popular spirits, Diageo and Jose Cuervo owner Becle, are at risk from U.S. President-elect Donald Trump's planned tariffs on Mexico, according to Mexican customs data reviewed by Reuters. Trump, who takes office on Jan. 20, has said he will slap 25% tariffs on imports...
Copyright 2023-2026 - www.financetom.com All Rights Reserved